Cleaning validation and verification in a high potent granulation suite

Published: 17-Nov-2022 Featured companies: PCI Pharma Services
Manufacturing Dosage Forms

Download the roundtable discussion for free

When manufacturing highly potent solid oral dosage forms, taking an effective approach to cleaning the equipment used is paramount. Manufacturing Chemist Editor Dr Kevin Robinson recently caught up with PCI Pharma Services process experts Ben Potter, Amala Alex and Richard Parry to learn more about cleaning validation and verification, the differences between the two … and why they’re so important. 

Download the roundtable discussion today. 

Featured companies

PCI Pharma Services: Your bridge between life-changing therapies and patients.
See more

You may also like

Manufacturing

Rare diseases and the integrated CDMO support system

Read more
In medicine, rarity is both a curse and a calling. When it comes to rare diseases, some may affect only a handful of families worldwide; yet the lack of scale does nothing to lessen the weight of those patients who are suffering

Trending Articles

  1. AFYREN obtains FSSC 22000 certification for industrial site The AFYREN NEOXY plant is now certified for the production and processing of biobased monocarboxylic acids and their derivatives for the food and feed industries, a guarantee of trust and performance for customers
  2. Top 10 tips for optimal rotary evaporation with Vacuubrand Labtex shares: "In the UK, we supply a comprehensive range of high-quality laboratory and instrumentation vacuum pumps from our trusted partners at Vacuubrand - world leaders in vacuum technology!"
  3. Navigating AI regulation for digital medical devices in global markets New whitepaper outlines regulatory pathways for AI-powered medical technologies in the UK, US and EU
  4. Extract Technology fully integrates into Dec Group and unveils new company name Dec Group UK reflects unified vision and strengthened capabilities for global customers
  5. IMA strengthens aseptic and containment capabilities with ProSys acquisition The deal expands IMA’s isolator and sampling technology portfolio for the global biopharmaceutical market

Relevant companies

See more

Upcoming event

DCAT Week

23–26 March 2026 | Conference | New York, US See all

You may also like

Manufacturing

Rare diseases and the integrated CDMO support system

In medicine, rarity is both a curse and a calling. When it comes to rare diseases, some may affect only a handful of families worldwide; yet the lack of scale does nothing to lessen the weight of those patients who are suffering
Manufacturing

Ultra-high potency and its impact on pharmaceutical outsourcing

This article explores the emerging distinction between high and ultra-high potency APIs, highlighting the implications for pharmaceutical outsourcing and risk management in an evolving therapeutic landscape
Manufacturing

The changing face of pharma outsourcing

CDMOs are evolving from service providers to strategic partners driving innovation and speed in drug development
Manufacturing

Agility, scale and trust: the outsourcing model driving pharma forward

Outsourcing in the pharmaceutical industry has long been viewed as a matter of convenience and a way to ease short-term capacity pressures or delay the decision to invest in costly new facilities. That framing no longer fits
Manufacturing

At BIO Show in Boston, PCI Pharma Services to provide updates on new manufacturing facility

For leading CDMO, qualification activities for plant’s state-of-the-art sterile fill-finish and lyophilisation line are underway, with GMP production commencing summer 2025
Manufacturing

Targeted protein degraders: transforming oral therapeutics

Targeted protein degraders (TPDs) are redefining modern drug discovery and development, offering a revolutionary approach to treating diseases that were once considered to be untreatable
Manufacturing

PCI Pharma Services acquires Ajinomoto Althea, makes ground on US and European expansion

PCI's acquisition of US-based sterile fill-finish CDMO Ajinomoto Althea is part of the company's overarching strategy to expand its drug delivery services within the US and Europe
Subscribe now